Parasitic eye infections tied to contact lens solution

Article

An inspection conducted by the US Food and Drug Administration determined that a subsidiary of Abbott Park, Ill.-based Abbott Laboratories Inc. failed to disclose multiple reports of a serious parasitic eye infection for more than a year.

An inspection conducted by the US Food and Drug Administration determined that a subsidiary of Abbott Park, Ill.-based Abbott Laboratories Inc. failed to disclose multiple reports of a serious parasitic eye infection for more than a year.

Law firm Schmidt & Clark's managing partner, Michael Schmidt, says the documents reveal the link between Acanthamoeba Keratitis and a popular contact lens solution sold by AMO.

"It confirms our suspicion that AMO knew, or should have known, that there was a significant increase in Acanthamoeba Keratitis cases associated with Complete MoisturePlus," Mr Schmidt says in the article.

The report, obtained under the Freedom of Information Act, revealed that FDA inspectors discovered that AMO failed to disclose at least nine reported cases of the sight-threatening eye infection Acanthamoeba Keratitis among users of the company's Complete MoisturePlus contact lens solution.

According to the report, AMO began receiving complaints of serious corneal infections in February 2006, but those reports were not disclosed until an FDA inspection in late May and early June 2007. The Centres for Disease Control launched its own investigation after receiving increasing reports of the rare infection.

AMO finally recalled Complete MoisturePlus in May 2007 after the release of data showed that users of the product were seven times more likely to be infected with Acanthamoeba Keratitis than those who never used Complete MoisturePlus. The FDA subsequently categorized the withdrawal as a Class I recall, a status reserved for situations where there is a reasonable probability that the recalled product will cause serious health problems or deaths.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.